Key Highlights

  • The first participant in Regimen I of the HEALEY ALS Platform Trial has moved into the Active Treatment Extension after completing 36 weeks of randomised treatment.
  • Regimen I has fully enrolled 250 participants across 78 US clinical sites, with topline results from the RCT anticipated in late Q2 CY2027.
  • The extension will provide all participants with investigational NUZ-001, regardless of their original allocation.
  • Recent written feedback from the US Food and Drug Administration noted Regimen I may serve as a single registrational study, subject to results and confirmatory evidence.

Neurizon Therapeutics Limited (ASX:NUZ) has announced that the first participant in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial has completed the 36-week placebo-controlled randomised phase and entered the Active Treatment Extension. The Melbourne-based clinical-stage biotechnology company is developing NUZ-001 as a potential treatment for amyotrophic lateral sclerosis, the most common form of motor neurone disease.

Progress Through the Regimen I Trial

Regimen I completed enrolment of 250 participants in July 2026. Participants are randomised 3:1 to NUZ-001 or placebo for 36 weeks, after which eligible participants may voluntarily continue into an optional 36-week extension. The company reported that enrolment across 78 activated US clinical sites took around five months, which it said was the fastest enrolment in ALS trial history. The primary evaluation of the study combines functional decline, measured using the ALS Functional Rating Scale-Revised, with survival.

The Active Treatment Extension is designed to collect additional longer-term safety, tolerability, functional and biomarker data. All participants entering the extension receive NUZ-001 under the trial protocol, irrespective of their original treatment allocation. Treatment assignments remain blinded during the extension. Participants will continue regular clinical and safety assessments, including respiratory function and quality of life measures, while blood and urine biomarker assessments such as neurofilament light chain will run throughout the period.

Regulatory Feedback and Evidence Package

Neurizon said the extension is not a separate controlled assessment of efficacy. The company expects the additional observations to complement the randomised trial dataset and contribute to the broader clinical evidence package for NUZ-001. Any contribution of extension data to a future regulatory submission remains subject to applicable requirements.

The company also referred to written feedback from the US Food and Drug Administration. According to Neurizon, the FDA noted that positive results from the HEALEY ALS Platform Trial may support a traditional approval pathway, and that Regimen I may serve as a single registrational study for NUZ-001. That feedback is subject to the trial results and confirmatory evidence meeting the applicable regulatory requirements. Neurizon’s stated next steps include completing the RCT phase, progressing toward database lock and delivering topline results in late Q2 CY2027. Those results will inform subsequent engagement with the FDA and other regulators on a potential approval pathway.

Trial Partners and Stated Management Views

Neurizon will continue working with the Healey & AMG Center for ALS at Mass General Brigham as participants progress through their treatment periods. Chief Executive Officer Dr Chris Bremer described the transition into the extension as an important milestone for Regimen I. Merit Cudkowicz, Executive Director of the Mass General Brigham Neuroscience Institute and Director of the Healey & AMG Center for ALS, said the platform was designed to reach clear answers in the shortest time, working with the Network for Excellence in ALS and a patient advisory committee to accelerate study start-up and maintain retention.

The company has noted that NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction. The outcome of the randomised phase remains unknown until topline results are released.

Closing Perspective

The extension marks a procedural step in a trial whose central efficacy question will not be answered until the randomised results arrive in late Q2 CY2027. The extension will add longer-term safety and biomarker information, but Neurizon has stated that it does not replace the controlled assessment at the centre of the study. Observers following the company are likely to focus on the database lock, the topline readout and any subsequent regulatory discussions about the potential approval pathway for NUZ-001.